Patents Assigned to Amgen
  • Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
    Publication number: 20070142384
    Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.
    Type: Application
    Filed: February 24, 2005
    Publication date: June 21, 2007
    Applicant: AMGEN INC.
    Inventors: Michelle Akerman, Jonathan Houze, Daniel Lin, Jinqian Liu, Jiwen Liu, Jian Luo, Zhihua Ma, Julio Medina, Wei Qiu, Jeffrey Reagan, Rajiv Sharma, Michael Schmitt, Stephen Shuttleworth, Ying Sun, Yingcai Wang, Jian Zhang, Liusheng Zhu
  • Fused heterocyclic compounds
    Publication number: 20070135425
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
    Type: Application
    Filed: January 5, 2007
    Publication date: June 14, 2007
    Applicant: Amgen Inc.
    Inventors: Xiaoqi Chen, Kang Dai, Pingchen Fan, Shugui Huang, Leping Li, Jeffrey Mihalic
  • Sitosterolemia susceptibility gene (SSG) polypeptides
    Patent number: 7229816
    Abstract: The present invention provides polypeptides of a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: June 12, 2007
    Assignee: Amgen Inc.
    Inventors: Hui Tian, Joshua Schultz, Bei Shan
  • Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)
    Patent number: 7226758
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Grant
    Filed: September 17, 1992
    Date of Patent: June 5, 2007
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • IL-17 like molecules and uses thereof
    Publication number: 20070123459
    Abstract: Novel IL-17 like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof.
    Type: Application
    Filed: October 6, 2006
    Publication date: May 31, 2007
    Applicant: AMGEN INC.
    Inventors: Eugene Medlock, Richard Yeh, Scott Silbiger, Gary Elliott, Hung Nguyen, Shuqian Jing
  • Salts and polymorphs of a potent antidiabetic compound
    Patent number: 7223761
    Abstract: Salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. In particular, the invention provides salts and polymorphs of a compound which modulates the expression and/or function of a peroxisome proliferator-activated receptor. The salts and polymorphs are useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: May 29, 2007
    Assignee: Amgen Inc.
    Inventors: Henry T. Kruk, Lawrence R. McGee, Bing Yang
  • Enhanced solubility of recombinant proteins
    Patent number: 7223742
    Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with a member of the 14-3-3 family of proteins.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: May 29, 2007
    Assignee: Amgen Inc.
    Inventor: Marshall Davenport Snavely
  • Novel activin receptor and uses thereof
    Publication number: 20070117130
    Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
    Type: Application
    Filed: October 31, 2006
    Publication date: May 24, 2007
    Applicant: Amgen Inc.
    Inventors: Hq Han, Keith Kwak, Xiaolan Zhou
  • Human E3? ubiquitin ligase family
    Patent number: 7220547
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: May 22, 2007
    Assignee: Amgen, Inc.
    Inventors: Hui-Quan Han, Keith Kwak
  • G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
    Patent number: 7220407
    Abstract: The present invention relates to methods of using Granulocyte Colony Stimulating Factor (G-CSF) polypeptide in conjunction with reperfusion therapy in the treatment of acute myocardial infarction or other ischemic events. This treatment can be used alone or in combination with other well-known methods of treatment.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: May 22, 2007
    Assignee: Amgen Inc.
    Inventors: Jayesh Mehta, Seema Singhal, Charles Davidson, Nirat Beohar, Robert Bonow
  • Binding agents
    Publication number: 20070110747
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Application
    Filed: April 25, 2006
    Publication date: May 17, 2007
    Applicants: UCB S.A., Amgen, Inc.
    Inventors: Christopher Paszty, Martyn Robinson, Kevin Graham, Alistair Henry, Kelly Hoffmann, John Latham, Hsieng Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David Winkler, Aaron Winters
  • Glycosylation analogs of erythropoietin
    Patent number: 7217689
    Abstract: Erythropoietin analogs having at least one additional site for glycosylation, or a rearrangement of at least one site for glycosylation are disclosed. The invention also relates to DNA sequences encoding said erythropoietin analogs, and recombinant plasmids and host cells for analog expression.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 15, 2007
    Assignee: Amgen Inc.
    Inventors: Steven G. Elliott, Thomas E. Byrne
  • Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
    Publication number: 20070099836
    Abstract: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.
    Type: Application
    Filed: November 29, 2006
    Publication date: May 3, 2007
    Applicants: Amgen, Inc., The Govt. of the U.S.A. as represented by the Secretary, Dept. of Health & Human Services, Board of Regents, The University of Texas System
    Inventors: Alexander DePaoli, Simeon Taylor, Elif Oral, Abhimanyu Garg
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070093419
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: April 26, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070093418
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: April 26, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Methods of increasing lean tissue mass using OB protein compositions
    Patent number: 7208577
    Abstract: The present invention provides methods of creating and using OB protein compositions with an antibody constant region or portion thereof fused to an OB protein. The fusion protein is created by attaching the polyamino acids to the OB protein moiety. The fusion proteins can then be used for various therapeutic uses.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: April 24, 2007
    Assignee: Amgen, Inc.
    Inventors: Mary Ann Pelleymounter, Christopher Francis Toombs, Michael Benjamin Mann
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Patent number: 7205275
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: April 17, 2007
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Cyclic amine derivatives and methods of use
    Patent number: 7199244
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: April 3, 2007
    Assignees: Amgen, Array Biopharma Inc.
    Inventors: Robert D. Groneberg, James Zhan, Benny C. Askew, Jr., Derin C. D'Amico, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Jiawang Zhu, Kevin Yang, Jian Jeffrey Chen, Rana Nomak
  • Antiinflammation agents
    Patent number: 7199119
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: April 3, 2007
    Assignee: Amgen Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, XianYun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
  • Stem cell factor
    Publication number: 20070071714
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Application
    Filed: September 7, 2006
    Publication date: March 29, 2007
    Applicant: AMGEN INC.
    Inventors: Krisztina Zsebo, Robert Bosselman, Sidney Suggs, Francis Martin